Renaissance Capital logo

Xeris Pharmaceuticals Priced, Nasdaq: XERS

Developing a novel formulation of an injectable hypoglycemia treatment.

Industry: Health Care

First Day Return: +34.8%

Industry: Health Care

We are a specialty pharmaceutical company leveraging our novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. We have developed a ready-to-use, room-temperature stable liquid glucagon formulation that, unlike any currently available products, can be administered without any preparation or reconstitution. Our lead product candidate, Glucagon Rescue Pen, delivers ready-to-use glucagon via a commercially-available auto-injector for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes. We have completed three Phase 3 clinical trials for our Glucagon Rescue Pen and expect to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or the FDA, in the third quarter of 2018. If our NDA is submitted and approved in our expected timeframe, we believe we will have the first ready-to-use, room-temperature stable liquid glucagon formulation that can be administered without any preparation or reconstitution. We are also applying our novel ready-to-use, room-temperature stable liquid glucagon formulation for the management of additional conditions associated with hypoglycemia with significant unmet medical need. In addition, we are applying our technology platforms to convert other commercially-available drugs into ready-to-use, room-temperature stable liquid formulations to address the needs in multiple therapeutic areas and conditions, including epilepsy and diabetes.
more less
IPO Data
IPO File Date 05/24/2018
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.7
Deal Size ($mm) $86
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/20/2018
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $86
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Chicago, IL, United States
Founded 2005
Employees at IPO 50
Website www.xerispharma.com

Xeris Pharmaceuticals (XERS) Performance